Status:
TERMINATED
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.
Detailed Description
Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated wit...
Eligibility Criteria
Inclusion
- Ambulatory outpatients with moderate to severe dementia of the Alzheimer's type who have completed the 24-week Study 10158 and who have a knowledgeable and reliable caregiver who will accompany the patient to all clinic visits during the course of the study.
Exclusion
- Diseases/medication which judged by the investigator could interfere with the assessments of safety, tolerability or efficacy.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
297 Patients enrolled
Trial Details
Trial ID
NCT00857233
Start Date
June 1 2004
End Date
October 1 2010
Last Update
August 29 2012
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
CA019
Edmonton, Alberta, Canada, T5G 0B7
2
CA033
Kelowna, British Columbia, Canada, V1W 4V5
3
CA043
Kelowna, British Columbia, Canada, V1Y 3G8
4
CA042
Penticton, British Columbia, Canada, V2A 5C8